The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 8, 2012, Pages 1699-1704

  Chen, Y H ^a,b   Ko, W C ^c   Hsueh, P R ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ACUTE PYELONEPHRITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ASIA; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM MUTANT; BLOODSTREAM INFECTION; CONCENTRATION RESPONSE; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PACIFIC ISLANDS; PREDICTION; PRIORITY JOURNAL; REVIEW; SUICIDAL IDEATION; SYNCOPE; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; ASIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PACIFIC ISLANDS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84866411447     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1457-x     Document Type: Review

References (44)

1. Schappert SM, Burt CW (2006) Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. Vital Health Stat 159:1-66
2. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl 1A):5S-13S (Pubitemid 34756640)
3. Chant C, Smith OM, Marshall JC, Friedrich JO (2011) Relationship of catheter-associated urinary tract infection to mortality and length of stay in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Med 39:1167-1173
4. van der Kooi TI, de Boer AS, Manniën J, Wille JC, Beaumont sMT, Mooi BW et al (2007) Incidence and risk factors of deviceassociated infections and associated mortality at the intensive care in the Dutch surveillance system. Intensive Care Med 33:271-278 (Pubitemid 46221232)
5. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L et al (2009) The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 34:407-413
6. Badal R BS, Hawser S, Hoban D, Hackel M, Hsueh PR (2010) Antimicrobial susceptibility of urinary tract Infection pathogens in Asia-SMART 2009. In: Proceedings of the 12th Western Pacific Congress on Chemotherapy and Infectious Diseases, Singapore, December 2010, abstract no. P026
7. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120
8. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC et al (2010) Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 50:625-663
9. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG (2008) European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents 31(Suppl 1):S68-S78
10. Infectious Diseases Society of the Republic of China, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, Lee CY's Research Foundation for Pediatric Infectious Diseases and Vaccine (2000) Guidelines for antimicrobial therapy of urinary tract infections in Taiwan. J Microbiol Immunol Infect 33:271-272
11. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ, EMERGEncy ID NET Study Group (2008) Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 47:1150-1158
12. Lau SM, Peng MY, Chang FY (2004) Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. J Microbiol Immunol Infect 37:185-191
13. Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S21. CLSI, Wayne, PA, USA
14. Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M et al (2011) Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 63:114-123
15. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG (2006) Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 50:2251-2254 (Pubitemid 43807558)
16. Sahuquillo-Arce JM, Selva M, Perpiñán H, Gobernado M, Armero C, López-Quílez A et al (2011) Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location. Antimicrob Agents Chemother 55:1222-1228
17. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B et al (2006) Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27:468-475
18. Viray M, Linkin D, Maslow JN, Stieritz DD, Carson LS, Bilker WB et al (2005) Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol 26:56-62 (Pubitemid 40110969)
19. Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD et al (2008) Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 121:876-884
20. Khawcharoenporn T, Vasoo S, Ward E, Singh K (2010) High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med (in press). doi:10.1016/j.ajem.2010.09.030
21. van der Starre WE, van Nieuwkoop C, Paltansing S, van't Wout JW, Groeneveld GH, Becker MJ et al (2010) Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 66:650-656
22. Lin CY, Huang SH, Chen TC, Lu PL, Lin WR, Chen YH (2008) Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates. J Microbiol Immunol Infect 41:325-331
23. Anderson VR, Perry CM (2008) Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 68:535-565 (Pubitemid 351342021)
24. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE (1999) Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 29:745-758 (Pubitemid 30256361)
25. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M et al (2002) Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 34:1165-1169 (Pubitemid 34450662)
26. Bolon MK (2009) The newer fluoroquinolones. Infect Dis Clin North Am 23:1027-1051
27. Frimodt-Møller N (2002) Correlation between pharmacokinetic/ pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19:546-553 (Pubitemid 34831659)
28. Schentag JJ (2000) Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis 31(Suppl 2):S40-S44 (Pubitemid 32269608)
29. Croom KF, Goa KL (2003) Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769-2802 (Pubitemid 38049994)
30. Naber KG (2001) Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 17:331-341 (Pubitemid 32293535)
31. Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M (2011) Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Res Microbiol 162:249-252
32. Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B (2011) Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebocontrolled trial. Clin Infect Dis 52:23-30
33. Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG (2009) Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother 53:1567-1573
34. Stein GE, Schooley SL, Nicolau DP (2008) Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents 32:320-325
35. Deguchi T, Nakane K, Yasuda M, Shimizu T, Monden K, Arakawa S et al (2010) Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/ pharmacodynamic analysis. Int J Antimicrob Agents 35:573-577
36. Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS et al (2009) Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 28:1013-1017
37. Sánchez Navarro MD, Coloma Milano C, Zarzuelo Castañeda A, Sayalero Marinero ML, Sánchez-Navarro A (2002) Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. Clin Pharmacokinet 41:1213-1220 (Pubitemid 35398693)
38. Wagenlehner FM, Kinzig-SchippersM, Tischmeyer U,Wagenlehner C, Sörgel F, Dalhoff A et al (2006) Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 27:7-14 (Pubitemid 43042416)
39. Drago L, Nicola L, Mattina R, De Vecchi E (2010) In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations. BMC Microbiol 10:119
40. Yang S, Clayton SR, Zechiedrich EL (2003) Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J Antimicrob Chemother 51:545- 556 (Pubitemid 36336146)
41. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 53:235-241
42. Miller LG, Mehrotra R, Tang AW (2007) Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? Int J Antimicrob Agents 29:605-607 (Pubitemid 46560357)
43. Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC et al (2007) A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 23:2637-2645 (Pubitemid 350146402)
44. Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB (2010) Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis. Curr Med Res Opin 26:1433- 1441